Trandolapril
Trandolapril structure
|
Common Name | Trandolapril | ||
|---|---|---|---|---|
| CAS Number | 87679-37-6 | Molecular Weight | 430.537 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 626.0±55.0 °C at 760 mmHg | |
| Molecular Formula | C24H34N2O5 | Melting Point | 122-123°C | |
| MSDS | Chinese USA | Flash Point | 332.4±31.5 °C | |
|
Tarka® (trandolapril/verapamil hydrochloride extended-release) overdose.
J. Emerg. Med. 40(3) , 291-5, (2011) Patients with fixed-dose combination product overdoses involving verapamil and trandolapril may present differently than sole calcium channel blocker (CCB) or angiotensin-converting enzyme inhibitor (ACE-I) overdose alone, and may have implications for the to... |
|
|
Dual therapy versus monotherapy of trandolapril and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats.
J. Renin Angiotensin Aldosterone Syst. 12(3) , 169-75, (2011) To investigate the combination of telmisartan with trandolapril therapy versus monotherapy of trandolapril and telmisartan on diabetic nephropathy in type 2 diabetes mellitus rats.Neonatal rats (2 days old) were used for inducing type 2 diabetes mellitus. Str... |
|
|
Tarka® overdose in a young child.
Hum. Exp. Toxicol. 30(9) , 1392-8, (2011) Tarka® is a combination antihypertensive medication composed of verapamil hydrochloride and trandolapril. A 3.5-year-old female was brought to our hospital due to a sleepy condition 7 hours after an accidental ingestion of six tablets of Tarka® containing 240... |
|
|
Similar renoprotection after renin-angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects?
Clin. Exp. Pharmacol. Physiol. 37(12) , 1159-69, (2010) 1. Hypertension plays a critical role in the progression of chronic kidney disease (CKD) to end-stage renal disease (ESRD), but it has also been postulated that antihypertensive drugs that block the renin-angiotensin system (RAS) show class-specific renoprote... |
|
|
Trandolapril, but not verapamil nor their association, restores the physiological renal hemodynamic response to adrenergic activation in essential hypertension.
Transl. Res. 157(6) , 348-56, (2011) The purpose of this study was to evaluate the effects of antihypertensive drugs on renal hemodynamics in hypertensive patients during an adrenergic activation by mental stress (MS), which induces renal vasoconstriction in healthy subjects. Renal hemodynamics ... |
|
|
Safety profile of the combination of verapamil and trandolapril.
J. Hypertens. Suppl. 15(2) , S51-3, (1997) ADVANTAGES OF DRUG COMBINATIONS: The particular advantage usually sought with antihypertensive drug combinations is an improvement in blood pressure control. However, at least as important is a consideration of adverse reactions and the safety of the combinat... |
|
|
Impurity profiling of trandolapril under stress testing: Structure elucidation of by-products and development of degradation pathway.
Int. J. Pharm. 438(1-2) , 61-70, (2012) Various regulatory authorities like International Conference on Harmonization (ICH), US Food and Drug Administration, Canadian Drug and Health Agency are emphasizing on the purity requirements and the identification of impurities in active pharmaceutical drug... |
|
|
Trandolapril: a newer angiotensin-converting enzyme inhibitor.
Clin. Ther. 25(3) , 713-75, (2003) Trandolapril is a newer angiotensin-converting enzyme (ACE) inhibitor that is approved by the US Food and Drug Administration for the treatment of hypertension and for use in stable patients who have evidence of left ventricular (LV) systolic dysfunction or s... |
|
|
Vascular affinity of trandolapril.
Am. J. Hypertens. 8(10 Pt 2) , 63S-67S, (1995) This article discusses the pharmacologic basis on which trandolapril exhibits a more potent and longer-lasting antihypertensive effect than its chemical prototype enalapril. Our studies have shown that 1) trandolapril and its active metabolite trandolaprilat ... |
|
|
Fixed combination verapamil SR/trandolapril.
Drugs 56(5) , 837-44; discussion 845-6, (1998) Verapamil sustained-release (SR)/trandolapril is a combination of a phenylalkylamine calcium antagonist and an angiotensin converting enzyme inhibitor for the management of essential hypertension. Verapamil SR/trandolapril does not adversely influence glucose... |